Arvinas (ARVN) in our Pivotal Point Check: Groundbreaking PROTAC Drugs and Analyst Upgrade Drive the Biotech Company up Over 20% after Quarterly Results!
Reading Time: 2 minutes
Arvinas is developing a new class of drugs called PROTAC to selectively degrade disease-causing proteins. The focus is on developing therapies in the fields of oncology (cancer) and neuroscience. Stephens raised the price target considering the quarterly earnings released shortly before. Arvinas is a clinical-stage biotechnology company. The company is developing a new class of oral medications known as PROTACs (PROteolysis TArgeting Chimeras). What sets PROTAC drugs apart is that they utilize the body's natural protein disposal...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
